Evidence map›Paper›PMID 42010634›Full record

ArticleAlzheimer's research & therapy2026

Connecting HTT intermediate alleles and microRNA dysregulation to enhanced tauopathy in late-onset Alzheimer's disease.

Juan Castilla-Silgado, Sergio Perez-Oliveira, Paola Pinto-Hernandez, Manuel Fernandez-Sanjurjo, Maria Daniela Corte-Torres, Olaya Fernandez-Alvarez, Eduardo Iglesias-Gutierrez, Manuel Menendez-Gonzalez, Victoria Alvarez, Cristina Tomas-Zapico

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juan Castilla-Silgado *Department of Functional Biology (Physiology), University of Oviedo, 33006, Oviedo, Spain.
Sergio Perez-Oliveira *Health Research Institute of the Principality of Asturias (ISPA), Oviedo, 33011, Spain.
Paola Pinto-HernandezDepartment of Functional Biology (Physiology), University of Oviedo, 33006, Oviedo, Spain.
Manuel Fernandez-SanjurjoDepartment of Functional Biology (Physiology), University of Oviedo, 33006, Oviedo, Spain.
Maria Daniela Corte-TorresHealth Research Institute of the Principality of Asturias (ISPA), Oviedo, 33011, Spain.
Olaya Fernandez-AlvarezHealth Research Institute of the Principality of Asturias (ISPA), Oviedo, 33011, Spain.
Eduardo Iglesias-GutierrezDepartment of Functional Biology (Physiology), University of Oviedo, 33006, Oviedo, Spain.
Manuel Menendez-GonzalezHealth Research Institute of the Principality of Asturias (ISPA), Oviedo, 33011, Spain.
Victoria Alvarez *Health Research Institute of the Principality of Asturias (ISPA), Oviedo, 33011, Spain. victoria.alvarez@sespa.es.
Cristina Tomas-Zapico *Department of Functional Biology (Physiology), University of Oviedo, 33006, Oviedo, Spain.

Funding

Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología AYUD/2021/5134Instituto de Salud Carlos III AC20/00017
6 · The paper itself

Abstract

backgroundLate-onset Alzheimer´s disease (LOAD) is a heterogeneous disorder influenced by complex genetic factors. We previously described intermediate alleles (IAs; 27–35 CAG repeats) in the huntingtin (HTT) gene as potential modifiers in around 6% of AD population. The caudate nucleus, the most affected region in Huntington’s disease, is highly sensitive to these HTT CAG repeats. We hypothesized that HTT IAs induce gene expression deregulation, including altered microRNA (miRNA) profiles, leading to altered disease progression.

methodsWe investigated the impact of HTT IAs on LOAD progression by genotyping HTT CAG repeats in a cohort of 323 LOAD patients and 335 healthy controls. Comprehensive histopathological and molecular analyses were performed on caudate nucleus samples from a matched subcohort (6 healthy controls, 14 LOAD non-HTT IA carriers, and 13 LOAD HTT IA carriers).

resultsHTT IAs carriers patients exhibited decreased survival after disease onset compared to non-carriers. Histopathologically, while LOAD patients showed increased soluble HTT levels and altered tau pathology compared to controls, these changes were consistently and markedly exacerbated in HTT IA carriers. This phenotype was characterized by heightened diffuse HTT immunoreactivity and an advanced maturation of tau pathology, specifically a pronounced increase in neuronal tau 3R burden and 3R tau-enriched ghost tangles. Interestingly, this pathological state was associated with alterations in key splicing factors, including decreased SRSF6 levels and increased nuclear FUS-SFPQ complex assembly. Analysis of microRNA (miRNA) profiling in the caudate nucleus revealed that the LOAD-associated miRNA dysregulation was significantly amplified in HTT IA carriers, identifying a signature of five miRNAs (miR-100-5p, miR-218-5p, miR-27b-3p, miR-487-3p, and miR-9-3p). In silico modeling based on high-confidence sequence homology demonstrated that these miRNAs are predicted to target components of the nuclear spliceosome machinery, such as SRSF family, along with MAPT and HTT genes, suggesting a direct link to the observed tauopathy.

conclusionsOur findings underscore that HTT IAs as critical modifiers in LOAD progression through an miRNA-mediated dysregulation of splicing and proteostasis. Thus, identifying HTT IAs through routine blood genetic screening offers a practical, non-invasive biomarker for patient stratification, taking a step forward to personalized therapeutic strategies in LOAD.

Indexed as

Alzheimer DiseaseHuntingtin ProteinMicroRNAsTauopathiesAgedAged, 80 and overAllelesCaudate NucleusDisease ProgressionFemaleHumansMaleMiddle Agedtau ProteinsHTT protein, humanHuntingtin ProteinMicroRNAstau ProteinsAlternative splicingClinical heterogeneityPost-transcriptional regulationPrognosisProteinopathies

Identifiers

PMID42010634
PMCPMC13107814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.